Novartis AG（NVS）股票分析NVSNovartis AG

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Novartis AG is currently a hold. The stock is priced at $150.62, with a high RSI of 81.144 indicating it may be overbought. Despite a strong gross margin of 75.39% and a forward P/E of 14.71, recent pipeline setbacks, including the discontinuation of a key trial, raise concerns. The mixed analyst ratings suggest uncertainty, with only 8 out of 23 analysts recommending a buy. The main risk is the potential impact of clinical trial failures on future performance, which could affect investor confidence.

3 analysts cover NVS: 1 rate it Buy, 2 Hold and 0 Sell. The average price target is 127.75.